Company Name Shape Pharmaceuticals
Mailing Address 55 Cambridge Pkwy. Cambridge, MA 02142 USA
Company Description Shape Pharmaceuticals, Inc. is developing a novel, topical HDAC inhibitor, SHP-141, currently in early clinical development, for the treatment of patients with cutaneous T cell lymphoma (CTCL).
M&A Terms TetraLogic will make a $13 million up-front cash payment for Shape, followed by undisclosed potential development and commercialization milestones, as well as tiered royalties on product sales.